Brodalumab (AMG 827) is a human, anti-IL17 receptor monoclonal antibody that binds with high affinity to human IL-17 receptor A and blocks the biological activity of the pro-inflammatory cytokines IL-17A and IL-17F, resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. The gene discussed is IL17A; the disease is psoriasis.